Ativa Medical today announced that it has raised $15 million in new Series B equity funding, bringing its total equity financing to $23 million. $17 million, including convertible debt The funds will support the development of Ativa’s product in order to obtain approval from the Food and Drug Administration of the Ativa micro lab and preparations for commercial launch
The Global Union of Series B Investors shall include:
Ping and Ventures, venture capital division of Ping and Insurance
Hermed Capital, a partnership between Fosun Pharma and SK
Laboratory Corporation of America Holdings (LabCorp) (LH), the world’s leading diagnostic healthcare company.
Dian Diagnostics, China’s leading central laboratory service
U, GIMDx Oh, S -based in vitro diagnostic R&D and development of the Guangzhou Medical Improvement Unit
Diamond BioFund, the largest health care fund in Taiwan
‘We thank our new investors for their support for Ativa and for the critical global market insight and market access they have provided,’ said James McNally, Ph.D. D. D. , CEO of Ativa ‘Beyond North America, we believe Asia will be the world’s largest market for point-of-care in vitro diagnostics, which is why we are particularly thrilled with our newest partners. ”
The Ativa micro lab miniaturizes the power of some larger and more expensive central lab blood test instruments in a single countertop system to help health providers make informed treatment decisions more quickly. ‘Our mission at Ativa is to help clinicians make faster treatment decisions that will improve patient outcomes,’ said David Deetz, co-founder and Chief Technology Officer at Ativa. The Ativa analyzer requires only a few drops of blood to perform many of the most common blood tests within 5 minutes, allowing providers to order, run and review the results of the lab in real time in front of their patients.
‘Efficiency and information is key to positive medical outcomes. The Ativa micro lab is a cost-effective solution and adds value to our expanding national clinical and care delivery programs,” said Jiang Zhang, director of Ping An Ventures. ‘Our goal is to cooperate globally with talented partners such as Ativa to bring technology to market for the benefit of our 200 million customers. ”
Jiang Zhang, director of Ping An Ventures, will join the board of directors of Ativa. Ativa is also pleased to recognize the value added to Med Qiao’s strategy and relations in Asia
‘As China’s leading independent commercial lab, Dian has always been looking for new technologies and newly developed tests globally to deliver quality medical services to clients,’ said Wilson Zhang, Director of Business Development, Dian Diagnostics. ‘This new technology can help Dian expand fast diagnostic results across the nation and help reduce medical insurance costs. ”
Dr. Dr. Larry Liu, President and CEO of GIMDx, said, “We are very pleased to invest in Ativa and look forward to our professional collaboration in R&D and marketing in China as this product has the potential to be vitally useful in many areas of IVD application. ”
The potential of the Ativa micro lab to complete commonly coordinated tests on one platform during a patient visit is central to the company’s vision. Ativa believes that its system will have applications for cellular analysis, support companion diagnostic testing for treatments such as immunotherapy, or may be of use in clinical research by making the trials more accessible.
‘We see a growing market for a solution like this that can address both health economic and clinical needs,’ said Haolin Sung, Director of Direct Investment, Diamond BioFund.
About the Ativa Medical Corps
Ativa Medical Corps Is a privately owned, emerging medical diagnostics company developing and commercializing novel diagnostic point-of-care technologies Ativa is pursuing the approval and commercialization of an innovative tabletop micro lab to enable healthcare professionals to perform on-site critical hematology and blood chemistry tests and to obtain accurate results in 5 minutes. Visit the www site Ativated Come on,
About the Ativa Micro Laboratory
Health care systems require companies to develop more efficient treatment models, as diagnostic testing drives 70% of medical decisions. Ativa’s micro lab will help clinicians make faster treatment decisions that could potentially improve patient outcomes. Designed to perform the most common blood-based laboratory tests in a clinical setting, the compact Ativa system combines flow cytometry, electrochemistry, colorimetric testing and imaging. Each test will run on a single, inexpensive, disposable card tailored to the test panel of choice. The Ativa system has advanced to demonstrate equivalence to much more expensive central lab systems. The technology of the system, including key microfluidic components, sample preparation, disposable test cards, diagnostic tests and instrumentation, is covered by multiple U Oh, S and international patents; See the Ativa system: Ativated Com/Video/MicroLAB For pictures of Ativa micro lab, go to www Ativated Com/Pictures Asp ASP
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Ativa%20Medical/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
